{"id":"cipterbin-combined-with-vinorelbine","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL553025","moleculeType":"Small molecule","molecularWeight":"778.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cipterbin is a tyrosine kinase inhibitor that targets growth factor signaling pathways in cancer cells. Vinorelbine is a semi-synthetic vinca alkaloid that binds to tubulin and prevents microtubule assembly, leading to mitotic arrest. The combination leverages complementary mechanisms to enhance cytotoxic effects against cancer cells.","oneSentence":"Cipterbin combined with vinorelbine uses a dual approach: cipterbin inhibits tumor cell signaling while vinorelbine disrupts microtubule dynamics to arrest cell division.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:30:06.529Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04681287","phase":"PHASE2","title":"Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2021-04-23","conditions":"HER2 Positive Metastatic Breast Cancer","enrollment":46},{"nctId":"NCT05131841","phase":"PHASE4","title":"Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-01-04","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT01439191","phase":"PHASE2","title":"Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Shanghai CP Guojian Pharmaceutical Co., Ltd.","startDate":"2005-07","conditions":"Metastatic Breast Cancer","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cipterbin Combined With Vinorelbine","genericName":"Cipterbin Combined With Vinorelbine","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cipterbin combined with vinorelbine uses a dual approach: cipterbin inhibits tumor cell signaling while vinorelbine disrupts microtubule dynamics to arrest cell division. Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}